On the Couch with Dr Chris Burns - CEO and MD Amplia Therapeutics (ATX)
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
On the Couch with Dr Chris Burns - CEO and MD Amplia Therapeutics (ATX)
-
ナレーター：
-
著者：
Welcome to the latest On the Couch. In this episode I am catching up with Chris Burns, the CEO and MD of Amplia Therapeutics (ATX).
Chris is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 25 years.
He has a Ph.D. from the University of Melbourne and is the inventor on over 30 patents and a co-author on over 60 scientific publications. He was co-recipient of the 2024 Prime Minister’s Prize for Innovation and is a Fellow of the Australian Academy of Health and Medical Sciences, the Royal Society of Chemistry (UK) and the Royal Australian Chemical Institute.
Dr Burns was originally appointed as a Non-Executive Director on 4 May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5 December 2022.
Amplia Therapeutics Limited (ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.